These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Managing advanced prostate cancer with Viadur (leuprolide acetate implant). Moul JW; Civitelli K Urol Nurs; 2001 Dec; 21(6):385-8, 393-4; quiz 395-6. PubMed ID: 11998504 [TBL] [Abstract][Full Text] [Related]
3. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Plosker GL; Brogden RN Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699 [TBL] [Abstract][Full Text] [Related]
4. Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer. Fowler JE; Urology; 2001 Sep; 58(3):430-4. PubMed ID: 11549494 [TBL] [Abstract][Full Text] [Related]
5. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. Wright JC; Tao Leonard S; Stevenson CL; Beck JC; Chen G; Jao RM; Johnson PA; Leonard J; Skowronski RJ J Control Release; 2001 Jul; 75(1-2):1-10. PubMed ID: 11451492 [TBL] [Abstract][Full Text] [Related]
6. Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs. Cukierski MJ; Johnson PA; Beck JC Int J Toxicol; 2001; 20(6):369-81. PubMed ID: 11797819 [TBL] [Abstract][Full Text] [Related]
8. Formulation study of leuprorelin acetate to improve clinical performance. Toguchi H Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592 [TBL] [Abstract][Full Text] [Related]
9. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations. Merseburger AS; Björk T; Whitehouse J; Meani D J Comp Eff Res; 2015 Sep; 4(5):447-53. PubMed ID: 25521079 [TBL] [Abstract][Full Text] [Related]
10. Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial. Crosignani PG; Gastaldi A; Lombardi PL; Montemagno U; Vignali M; Serra GB; Stella C Clin Ther; 1992; 14 Suppl A():29-36. PubMed ID: 1535020 [TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol]. Palagiano A; Capuano V Minerva Ginecol; 1994 Apr; 46(4):173-7. PubMed ID: 8065590 [TBL] [Abstract][Full Text] [Related]
13. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Berges R; Bello U Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425 [TBL] [Abstract][Full Text] [Related]
14. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Gerhard I; Schindler AE; Bühler K; Winkler U; Meinen K; Mancarella D; Hoffmann G; Schüssler B; Kimmig R; Kranzfelder D Clin Ther; 1992; 14 Suppl A():3-16. PubMed ID: 1535021 [TBL] [Abstract][Full Text] [Related]
15. Clinical studies investigating the use of leuprorelin in Asian women with endometriosis: a review. Osuga Y; Torng PL; Jeng CJ J Obstet Gynaecol; 2019 Apr; 39(3):291-296. PubMed ID: 30653368 [TBL] [Abstract][Full Text] [Related]
17. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations. Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810 [TBL] [Abstract][Full Text] [Related]
18. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Cox MC; Scripture CD; Figg WD Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462 [TBL] [Abstract][Full Text] [Related]
19. [Clinical study on the effectiveness and safety of combined laparoscopy and gonadotropin-releasing hormone agonist in the treatment of endometriosis]. Song JH; Lu H; Zhang J; Li B Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):584-8. PubMed ID: 24199923 [TBL] [Abstract][Full Text] [Related]